Dicerna Pharmaceuticals this week announced the publication of data by company researchers and collaborators demonstrating the potential therapeutic benefit of knocking down a key cancer target using RNAi.
Dicerna Pharmaceuticals this week announced that partner Kyowa Hakko Kirin has decided to advance a second cancer drug candidate into formal development as part of the companies' ongoing alliance.
The move has triggered a $5 million milestone payment to Dicerna.
Dicerna Pharmaceuticals said this week that it has reached another milestone in its collaboration with Kyowa Hakko Kirin after the Japanese pharmaceutical firm “recognized the successful achievement of an in vivo activity milestone” for a second oncology drug candidate.
LAS VEGAS — Dicerna Pharmaceuticals has selected a target and delivery technology for its first drug candidate, and remains on track to meet its previously stated goal of filing an investigational new drug application by the end of 2013, a company official disclosed this week.
Dicerna Pharmaceuticals announced this week that it has earned a $5 million milestone payment after partner Kyowa Hakko Kirin decided to further develop an oncology drug candidate covered by the companies' drug-development alliance.
Dicerna recently announced that its CEO had stepped down and will be replaced by company Co-Founder Doug Fambrough. He was a general partner at VC firm Oxford Bioscience Partners, an early investor in Sirna Therapeutics.
Under the terms of the arrangement, Dicerna will receive from Kyowa $4 million up front and up to $120 million in research funding and milestones in exchange for the exclusive rights to an undisclosed cancer target. Additional targets may be added to the arrangement under similar terms.